Free Psychiatry CME

  • FREE

    Free Psychiatry CME Courses from Pri-Med® – Designed for Primary Care Clinicians

    Individuals with depression, anxiety, bipolar disorder, and other psychiatric conditions first seek help from primary care providers like you. Our courses offer practical guidance on assessing and managing these can’t-miss diagnoses in your patients. Choose from a variety of free psychiatry CME courses to improve care for your patients. Earn credits at no cost today.

    See full details chevron_right
    • Cost: Free
    • Credit hours: Varies by Course
    • CME credits awarded by: pmiCME, the accredited division of Pri-Med®
    • Format: On-Demand Courses Online
    • Material last updated: Continuously Updated
    • Expiration of CME credit: Varies by Course
  • FREE

    Fact or Fiction? Test Your Knowledge on Residual and Treatment-Emergent Symptoms in Major Depressive Disorder

    Although major depressive disorder (MDD) has a profound impact on individuals, families, and society, it remains undertreated. There are currently more than 4 million US adults who are inadequately treated for MDD. Numerous studies show that antidepressant therapies are superior to placebo, but most adults with MDD do not achieve an adequate response with first-line pharmacotherapy. Inadequate response to antidepressant therapy is associated with greater medical morbidity, more hospitalizations, decreased productivity, and more suicide attempts. Treatment of MDD should strive for return to premorbid status and full functional and cognitive recovery. However, survey data show that health care providers may lack confidence in the management of patients who have an inadequate response to an antidepressant. The major barriers to achieving full recovery are the continuation of residual symptoms and treatment-emergent symptoms associated with antidepressants. Even in those responding to antidepressants, residual and treatment-emergent symptoms such as weight gain, sleep disturbance, and sexual dysfunction can impede adherence and recovery. Additionally, poor cognitive functioning is an obstacle to remission. Although tools are available for the evaluation and monitoring of cognitive function in patients with MDD, they remain underutilized. In this enduring activity, expert faculty will provide opportunities to enhance knowledge and competence in the ability to differentiate residual and treatment-emergent symptoms and better assess and manage symptoms using evidence-based strategies to optimize available therapies.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Medical Education Resources
    • Format: On-Demand Online
  • FREE

    Fact or Fiction? Test Your Knowledge on Assessment and Management Strategies in Tardive Dyskinesia

    At any given time, roughly one-quarter of individuals taking antipsychotics experience TD, a condition characterized by involuntary movements of the face and body. Moreover, as the use of antipsychotics has expanded to disorders such as depression, behavioral disorders, and dementia, TD is no longer primarily limited to patients with schizophrenia. TD has an outsized impact on patients’ ability to carry out daily tasks and interact with others. However, because TD has long been considered an irreversible consequence of the use of antipsychotics or other dopamine receptor–blocking agents, many clinicians have come to view it with a sort of “therapeutic nihilism.” As a result, many patients have not received treatment for their TD. Recently, the US FDA approved 2 medications, both vesicular monoamine transporter 2 (VMAT2) inhibitors, to treat TD, giving patients access to the first well-tolerated oral treatments shown to be effective for this condition. To ensure that patients receive maximum benefit from this advance in TD treatment, clinicians must learn how to integrate VMAT2 inhibitors into their practice. In this activity, an expert faculty member will dispel common myths about TD, educating clinicians about how to recognize and diagnose TD promptly, how VMAT2 inhibitors work to improve TD symptoms, how the 2 approved agents differ, and how VMAT2 inhibitors can be used alongside other strategies to improve outcomes for patients with TD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.5
    • CME credits awarded by: Medical Education Resources
    • Format: On-Demand Online
  • FREE

    One Size Does Not Fit All: Optimizing Use of Major Depressive Disorder Specifiers to Improve Outcomes

    Major depressive disorder (MDD) is a highly heterogeneous disorder that is increasingly seen as a continuum, with emphasis on overlapping and subthreshold symptoms. To address this issue, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) included the use of specifiers, such as mixed features and anxious distress, with the diagnosis of MDD. Although DSM-5 specifiers improve utility and precision in the diagnosis of MDD and related disorders, they may not be widely adopted because some clinicians maintain a categorical approach toward depression. The risk when clinicians avoid specifiers is significant because patients with diverse depressive illnesses should be diagnosed, monitored, and treated differently. Further, compared with MDD alone, the presence of mixed features or anxious distress in patients with MDD may be associated with diminished response to antidepressants, more severe symptoms, increased hospitalization, greater risk for suicide, and other deleterious outcomes. It is important for health care providers to appreciate the importance of MDD specifiers, their diagnostic criteria, and implications for evidence-based treatment. This activity was created to enhance knowledge and competence of health care providers who evaluate and manage patients with depression and clinical features of hypomania, mania, or anxiety.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.5
    • CME credits awarded by: Medical Education Resources
    • Format: On demand online
  • FREE

    ScientiaCME Neuropsychiatry – Psychiatry

    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release
  • FREE

    Binge Eating Disorder (BED): Therapeutic Updates, Best Practices, and Barriers to Care

    This free online CME self-learning program provides deep insights into Binge Eating Disorder (BED) and features commentary from experts on the topic.

    Topics covered in this program include

    • BED epidemiology
    • BED comorbidities
    • BED treatment
    • BED diagnosis

    After completing this course, you will better be able to:

    • Describe the importance of accurate diagnosis and treatment of BED.
    • Determine likelihood of BED using established methods in a patient case.
    • Describe available therapies used for treatment of BED and summarize* recent literature supporting use of those therapies
    • Design a therapeutic regimen, including pharmacotherapy, for the treatment of BED
    • Describe barriers preventing the optimal treatment of BED

    Target Audience: Psychiatrists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in psychiatry; and any other healthcare professionals with an interest in or who clinically encounter patients with BED.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: September 04, 2018
    • Expiration of CME credit: September 04, 2021
  • FREE

    CME: Improving the treatment and management of schizophrenia: an overview of current and novel approaches

    Schizophrenia, by nature, presents manifold challenges to the HCP directing neuropsychiatric care. Not only do practical matters like medication adherence play a role in the success of therapy, but it behooves clinicians to also have a well-informed understanding of the symptomatology and treatment course of the disease. Atypical antipsychotics are the mainstay of initial pharmacotherapy, with oral agents being preferred first. However, they have sometimes been associated with poor patient adherence, which is associated with suboptimal clinical outcomes. In contrast, improving adherence may enhance quality of life and reduce the risk of hospitalization, thereby potentially lowering health resource utilization and its associated costs.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of schizophrenia and the role the neurotransmitters receptors play in it: D2, D3, 5-HT2A
    • Describe the benefits and risks of pharmacotherapy for schizophrenia and take them into account when formulating a treatment plan for different patients
    • Formulate a treatment plan for a variety of patients with schizophrenia, including those exhibiting only negative symptoms
    • Recommend therapy changes in patients who are unable to tolerate a prescribed treatment
    • Identify barriers to care in patients with schizophrenia and develop** strategies to abate them

    Target Audience:

    Healthcare professionals who are: psychiatrists and primary care physicians; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in psychiatry; and those who otherwise commonly care for or clinically encounter patients who have schizophrenia.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/6/2020
    • Expiration of CME credit: 3/6/2022
  • FREE

    CME: Opioid dependence and opioid use disorder: best practices, barriers in care, and the role of long-acting injectable medication

    Opioid use disorder (OUD) affects millions of individuals globally and is best defined by the Diagnostic and Statistic Manual of Mental Disorders, Fifth Edition (DSM-5) as a condition due to tolerance, manifestation of physical dependence, and loss of control leading to health hazards.The scale of the problem is staggering, and while the causes are manifold, it is fueled in part by widespread availability: the Centers for Disease Control and Prevention estimates that the distribution of prescription opioid analgesics rose over fivefold between 1997 and 2007.

    By the end of the session the participant will be able to:

    • Describe the epidemiology of OUD and dependence, and outline current and the significance of inappropriate selection and treatment of opioid therapy
    • Identify long-acting treatment modalities for OUD and dependence, and apply them to patient cases using evidence-based medicine
    • Identify challenges associated with the selection and implementation of drug regimens to the treatment of OUD and dependence, including risk factors for opioid overdose
    • Develop strategies for recognizing and improving therapeutic adherence in patients treated for OUD and opioid dependence

    Target Audience:

    Healthcare professionals specializing in: addiction specialists, pain management specialists, primary care physicians, and psychiatrists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pain management or substance abuse; and any other health professionals who encounter OUD in the clinical setting.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 12/30/19
    • Expiration of CME credit: 12/30/21
  • FREE

    CME: Updates in the management of insomnia: therapeutic updates and optimizing treatment

    Insomnia is defined by the dissatisfaction of sleep quality or quantity characterized by having difficulty falling asleep, staying asleep, waking too early, or a combination of these. It is defined as chronic if the condition persists for three months, despite the opportunity for sleep or eradication of external stimulus. Insomnia affects people of all ages, though the likelihood of developing insomnia increases with age: reporting one-third of the adult population having been affected by at least one symptom of insomnia.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of insomnia such that it might inform treatment mechanisms
    • Identify the currently available and emerging pharmacotherapeutic treatments for management of insomnia and apply them to patient cases using evidence-based medicine
    • Evaluate a treatment plan for a specific patient with insomnia to optimize safety and efficacy, suggesting modifications for improvement
    • Describe barriers to care associated with treating patients with insomnia

    Target Audience: The following HCPs: neurologists, psychiatrists, sleep medicine specialists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in the aforementioned areas of specialty; and those who otherwise have an interest in or commonly care for or clinically encounter patients with insomnia.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/18/2019
    • Expiration of CME credit: 10/18/2021
  • FREE

    CME: Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents: Updates from APA 2019

    ADHD is a common neuropsychiatric disorder, estimated to affect 7.2% of school age children worldwide and 11% in the US. The presence of the disorder is often not detectable until school workload increases, and it has a significant impact on child and adolescent development, health, education, and family situations. There is evidence of a wide variability in clinicians’ ability to diagnose ADHD, suggesting opportunities for improvement and a gap in care that might be remedied by CME.

    By the end of the session the participant will be able to:

    • Summarize the most impactful findings presented at the APA 2019 meeting relating to pediatric ADHD related to disease diagnosis and apply them to patient cases.
    • Summarize the most impactful findings presented at the APA 2019 meeting relating to pediatric ADHD related to evaluation of degree therapeutic success and apply them to patient cases.
    • Summarize the most impactful findings presented at the APA 2019 meeting relating to pediatric ADHD related to emerging therapies and apply them to patient cases.
    • Summarize the most impactful findings presented at the APA 2019 meeting relating to pediatric ADHD related to quantifying benefit and risk of disease progression and apply them to patient cases.

    Target Audience:

    The following healthcare professionals: psychiatrists, primary care physicians, pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in psychiatry; and any other healthcare professionals with an interest in or who clinically encounter pediatric patients with ADHD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/6/19
    • Expiration of CME credit: 10/6/21